Small-cell Lung Cancer Clinical Trial
Official title:
Real-world Effectiveness and Treatment Sequences in Patients With Extensive Stage SCLC Who Received Lurbinectedin as Part of the French Early Access Program (ATU).
LURBICLIN cohort will describe the demographic and clinical characteristics of patients who received at least one dose of lurbinectedin as part of ATU program. LURBICLIN will evaluate effectiveness and safety of lurbinectedin in real-world conditions.
LURBICLIN cohort will describe the demographic and clinical characteristics of patients who received at least one dose of lurbinectedin as part of ATU program. LURBICLIN will evaluate overall survival, real world progression-free survival, best response and duration of treatment in patients with advanced, metastatic Small Cell Lung Cancer (SCLC) who received lurbinectedin as part of the French Early Access Program (ATU). Previous and subsequent treatments (treatment delivered immediately after treatment with lurbinectedin) will be recorded. Those outcomes will be correlated to clinical, pathological, and radiological characteristics of patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05552846 -
Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy
|
Phase 2 | |
| Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
| Recruiting |
NCT06022757 -
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04923776 -
Liver Directed RT + Chemo-immunotherapy for ES-SCLC
|
Phase 2 | |
| Recruiting |
NCT04168281 -
Watchful Observation of Patients With LD-SCLC Instead of the PCI
|
N/A | |
| Completed |
NCT03239171 -
Bioinformation Therapy for Lung Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04539977 -
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03345485 -
Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06103682 -
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
|
N/A | |
| Recruiting |
NCT04170946 -
Talazoparib and Thoracic RT for ES-SCLC
|
Phase 1 | |
| Recruiting |
NCT03523234 -
Neoadjuvant Therapy Combined With Radical Surgery for the Treatment of Small Cell Lung Cancer (SCLC) in II and IIIA Stage
|
N/A | |
| Recruiting |
NCT05620134 -
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05578326 -
Study of Trilaciclib and Lurbinectidin
|
Phase 2 | |
| Recruiting |
NCT06255197 -
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
|
||
| Terminated |
NCT04610658 -
Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC
|
Phase 1 | |
| Active, not recruiting |
NCT04116320 -
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT05091567 -
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
|
Phase 3 | |
| Terminated |
NCT04596033 -
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
|
Phase 1 | |
| Recruiting |
NCT06160596 -
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
|